Results 21 to 30 of about 541,695 (230)

Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells

Haematologica, 2011
Background The World Health Organization separates acute erythroid leukemia (erythropoiesis in ≥50% of nucleated bone marrow cells; ≥20% myeloblasts of non-erythroid cells) from other entities with increased erythropoiesis – acute myeloid leukemia with ...
Ulrike Bacher, Claudia Haferlach, Tamara Alpermann, Wolfgang Kern, Susanne Schnittger, Torsten Haferlach   +5 more
doaj   +1 more source

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. [PDF]

New England Journal of Medicine, 2016
J. Welch, A. Petti, Christopher A. Miller, C. Fronick, M. O'Laughlin, R. Fulton, R. Wilson, J. Baty, E. Duncavage, B. Tandon, Yi-Shan Lee, L. Wartman, G. Uy, A. Ghobadi, M. Tomasson, I. Pusic, R. Romee, T. Fehniger, K. Stockerl-Goldstein, R. Vij, S. Oh, C. Abboud, A. Cashen, M. Schroeder, Meagan A. Jacoby, S. Heath, K. Luber, M. Janke, A. Hantel, N. Khan, M. Sukhanova, R. Knoebel, W. Stock, T. Graubert, M. Walter, P. Westervelt, D. Link, J. Dipersio, T. Ley   +38 more
semanticscholar   +3 more sources

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.

The Journal of the National Comprehensive Cancer Network, 2021
The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding ...
D. Pollyea, D. Bixby, A. Perl, V. Bhatt, J. Altman, F. Appelbaum, M. de Lima, A. Fathi, J. Foran, I. Gojo, Aric Hall, Meagan A. Jacoby, J. Lancet, G. Mannis, G. Marcucci, Mike G Martin, A. Mims, Jadee L. Neff, R. Nejati, R. Olin, M. Percival, T. Prebet, Amanda C. Przespolewski, D. Rao, F. Ravandi-Kashani, P. Shami, R. Stone, S. Strickland, K. Sweet, P. Vachhani, M. Wieduwilt, K. Gregory, Ndiya Ogba, M. Tallman   +33 more
semanticscholar   +1 more source

Acute Myeloid Leukemia

Hematology, 2004
AbstractAdvances in our understanding of the pathophysiology of acute myeloid leukemia (AML) have not yet led to major improvements in disease-free and overall survival of adults with this disease. Only about one-third of those between ages 18–60 who are diagnosed with AML can be cured; disease-free survival is rare and current therapy devastating in ...
Richard M, Stone, Margaret R, O'Donnell, Mikkael A, Sekeres   +2 more
openaire   +4 more sources

Progress in Acute Myeloid Leukemia [PDF]

Clinical Lymphoma Myeloma and Leukemia, 2015
Significant progress has been made in the treatment of acute myeloid leukemia (AML). Steady gains in clinical research and a renaissance of genomics in leukemia have led to improved outcomes. The recognition of tremendous heterogeneity in AML has allowed individualized treatments of specific disease entities within the context of patient age ...
Kadia, Tapan M, Ravandi, Farhad, O'Brien, Susan, Cortes, Jorge, Kantarjian, Hagop M   +4 more
openaire   +5 more sources

NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia

Haematologica, 2008
Acute myeloid leukemia carrying NPM1 mutations and cytoplasmic nucleophosmin (NPMc+ acute myeloid leukemia) represents one-third of adult AML (50–60% of all acute myeloid leukemia with normal karyotype) and shows distinct biological, pathological and ...
Brunangelo Falini, Cristina Mecucci, Giuseppe Saglio, Francesco Lo Coco, Daniela Diverio, Patrick Brown, Fabrizio Pane, Marco Mancini, Maria Paola Martelli, Stefano Pileri, Torsten Haferlach, Claudia Haferlach, Susanne Schnittger   +12 more
doaj   +1 more source

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients

Haematologica, 2012
Background The hypocellular variant of acute myeloid leukemia accounts for less than 10% of all cases of adult acute myeloid leukemia. It is defined by having less than 20 percent of cellular bone marrow in a biopsy at presentation.
Aref Al-Kali, Sergej Konoplev, Erpei Lin, Tapan Kadia, Stefan Faderl, Farhad Ravandi, Mohamad Ayoubi, Mark Brandt, Jorge E. Cortes, Hagop Kantarjian, Gautam Borthakur   +10 more
doaj   +1 more source

De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

Cancer, 2021
Several important treatment and supportive care strategies have been implemented over the past 4 decades in the management of acute myeloid leukemia (AML).
K. Sasaki, F. Ravandi, T. Kadia, C. Dinardo, N. Short, G. Borthakur, E. Jabbour, H. Kantarjian   +7 more
semanticscholar   +1 more source